MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?


OverviewForecastFinancialsChartTranscripts

MoonLake Immunotherapeutics Ownership Summary


MoonLake Immunotherapeutics is owned by 11.88% institutional investors, 9.68% insiders, and 78.44% retail investors. Bvf inc/il is the largest institutional shareholder, holding 24.82% of MLTX shares. Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund, with 1.65% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics11.88%9.68%78.44%
SectorHealthcare Stocks 35.64%12.08%52.28%
IndustryBiotech Stocks 35.26%12.00%52.74%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il16.00M24.82%$298.26M
Deep track capital, lp6.41M9.94%$119.46M
Cormorant asset management, lp4.48M6.95%$83.52M
Janus henderson group3.45M5.35%$64.30M
D. e. shaw2.39M3.71%$44.56M
Avoro capital advisors2.00M3.16%$14.34M
Bioimpact capital1.81M2.81%$33.76M
Weiss asset management lp1.71M2.65%$31.84M
Adage capital partners gp1.50M2.37%$10.76M
Logos global management lp1.50M2.33%$27.96M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il16.00M9.50%$298.26M
Lion point capital, lp67.50K7.52%$1.26M
Cormorant asset management, lp4.48M4.19%$83.52M
Ghost tree capital300.00K4.13%$13.19M
Bioimpact capital1.81M2.61%$33.76M
Acuta capital partners191.76K2.52%$3.57M
Great point partners500.00K2.14%$9.32M
Exome asset management215.38K2.08%$4.01M
Deep track capital, lp6.41M1.95%$119.46M
Vivo capital1.00M1.56%$18.64M

Top Buyers

HolderShares% AssetsChange
Bioimpact capital1.81M2.61%1.81M
Deep track capital, lp6.41M1.95%1.80M
Adage capital partners gp1.50M0.02%1.50M
Weiss asset management lp1.71M0.54%1.38M
Janus henderson group3.45M0.03%1.36M

Top Sellers

HolderShares% AssetsChange
Bvf inc/il16.00M9.50%-3.75M
Avoro capital advisors2.00M0.19%-2.15M
Westfield capital management co lp---1.26M
Federated hermes---1.25M
Jane street group453.63K0.00%-1.23M

New Positions

HolderShares% AssetsChangeValue
Bioimpact capital1.81M2.61%1.81M$33.76M
Adage capital partners gp1.50M0.02%1.50M$10.76M
Holocene advisors, lp600.00K0.03%600.00K$11.18M
Great point partners500.00K2.14%500.00K$9.32M
Casdin capital450.00K0.64%450.00K$8.39M

Sold Out

HolderChange
National bank of canada /fi/-2.00
Wpg advisers-3.00
Montag a & associates-7.00
Creative financial designs inc /adv-10.00
Bryn mawr trust-12.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202678-46.21%7,657,293-86.41%110.15%41-58.16%25-10.71%
Dec 31, 202517-90.17%854,269-97.72%10.04%13-85.71%3-93.33%
Sep 30, 202530-79.31%901,952-98.46%10.02%17-73.02%9-83.64%
Jun 30, 2025145-2.03%58,588,368-0.85%921.06%63-11.27%5425.58%
Mar 31, 202515019.05%59,722,976-5.57%940.93%72-4343.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Jupiter Merian Glb Eq AbsRet I USD Acc1.18M1.65%1.18M
Polar Capital Biotech S Inc1.00M1.58%-
Fidelity Growth Compy Commingled Pl S981.02K1.54%273.63K
Jupiter Merian Glb Eq Abs Rt I USD Acc1.18M1.41%1.18M
Fidelity Growth Company Fund740.92K1.17%248.13K
T. Rowe Price Small-Cap Value918.59K1.10%647.15K
Federated Hermes Kaufmann Growth665.00K1.05%-
Federated Hermes Kaufmann R665.00K1.05%-
T. Rowe Price Health Sciences792.07K0.95%-147.16K
US Small-Cap Growth II Equity Comp523.89K0.83%-134.19K

Recent Insider Transactions


DateNameRoleActivityValue
Jul 21, 2026Reich Kristian Chief Scientific OfficerSell$1.00M
Jul 22, 2026Reich Kristian Chief Scientific OfficerSell$48.96K
Jul 20, 2026Reich Kristian Chief Scientific OfficerSell$877.93K
Jul 15, 2026Reich Kristian Chief Scientific OfficerSell$322.26K
Jul 09, 2026Santos da Silva Jorge Chief Executive OfficerSell$679.06K

Insider Transactions Trends


DateBuySell
2026 Q3-7
2026 Q2-12
2026 Q1-3
2025 Q414
2025 Q3-6

MLTX Ownership FAQ


Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 11.88%, followed by 9.68% insiders and 78.44% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 35.26%, which MoonLake Immunotherapeutics falls below.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (16M shares, 24.82%), Deep track capital, lp (6.41M shares, 9.94%), and Cormorant asset management, lp (4.48M shares, 6.95%). Together, they hold 41.71% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 9.50% of its assets in 16M MoonLake Immunotherapeutics shares, valued at 298.26M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.65% of its total shares outstanding invested in 1.18M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools